First Light Asset Management’s Celldex Therapeutics CLDX Stock Holding History

First Light Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-14,054	Closed	-$797K	–	68
2016 Q1	$797K	Buy	14,054 +164	+1%	+$18.5K	0.4%	41
2015 Q4	$3.27M	Sell	13,890 -452	-3%	-$98.5K	1.37%	29
2015 Q3	$2.27M	Buy	14,342 +1,986	+16%	+$562K	1.12%	32
2015 Q2	$4.67M	Buy	12,356 +1,080	+10%	+$429K	2.2%	18
2015 Q1	$4.71M	Buy	11,276 +1,035	+10%	+$370K	2.41%	14
2014 Q4	$2.8M	Buy	10,241 +720	+8%	+$179K	1.59%	23
2014 Q3	$1.85M	Buy	9,521 +231	+2%	+$50.3K	1.27%	26
2014 Q2	$2.27M	Buy	9,290 +453	+5%	+$102K	1.53%	25
2014 Q1	$2.34M	Buy	8,837 +1,097	+14%	+$420K	1.66%	25
2013 Q4	$2.81M	Buy	+7,740	New	+$2.98M	2.38%	16

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BIM

Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

First Light Asset Management's CLDX Position: Q2 2016 in Review

First Light Asset Management sold out of Celldex Therapeutics (CLDX) in Q2 2016, closing a stake of 14,054 shares — an estimated $797K sold.

First Light Asset Management first reported a position in CLDX in Q4 2013 and held it in 10 quarters. The position peaked at $4.71M in Q1 2015. 141 funds tracked by Wall St. Rank hold CLDX as of Q2 2016.

First Light Asset Management reported no remaining Celldex Therapeutics position as of Q2 2016 after selling out during the quarter.
First Light Asset Management sold 14,054 Celldex Therapeutics shares in Q2 2016, an estimated $797K.
First Light Asset Management first reported a position in Celldex Therapeutics in Q4 2013 and held it in 10 quarters.
First Light Asset Management's Celldex Therapeutics position peaked at $4.71M in Q1 2015.
141 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2016.

Based on First Light Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.